Literature DB >> 31497359

Indicators of multifocality in papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis.

Shuai Dong1, Xiao-Jun Xie1, Qing Xia2, Yi-Jun Wu1.   

Abstract

Currently, no definitive diagnostic tool is available to distinguish unifocal and multifocal papillary thyroid carcinoma (PTC). This study aims to identify potential diagnostic markers of multifocal PTC. In 471 Hashimoto's thyroiditis (HT) patients, the significant difference was revealed in anti-thyroid peroxidase antibody (TPOAb) concentration, the cytokeratin-19 (CK-19) expression, the occurrence of the B-Raf proto-oncogene serine/threonine kinase (BRAF) mutations and the rearrangement in transformation (RET)/PTC. The patients' samples were assayed for the expression of CK-19, cyclooxygenase-2 (COX-2), galectin-3, and the protein human bone marrow endothelial cell marker-1 (HBME-1) using immunohistochemistry. The BRAF gene mutation was detected using a sequencer. Differences were examined using the Kruskal-Wallis test and the Chi-squared and Fisher's exact tests. The results showed that the elevated CK-19 expression, and the presence of BRAF mutations and RET/PTC rearrangements were indicators of multifocal PTC in HT, suggesting the need for total bilateral thyroidectomy. Among HT patients with TPOAb > 1300 IU/Ml, the occurrence of central lymph node metastasis is significantly higher in multi-focal PTC than single-focal PTC. Therefore, these markers may prove useful for discerning between uni- and multifocal PTC, thereby preventing unnecessary surgery in the treatment of unifocal PTC and promoting sufficient treatment of multifocal PTC.

Entities:  

Keywords:  Hashimoto’s thyroiditis (HT); anti-thyroid peroxidase antibody (TPOAb); biomarker; papillary thyroid carcinoma (PTC); thyroidectomy

Year:  2019        PMID: 31497359      PMCID: PMC6726987     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  35 in total

1.  Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.

Authors:  Z W Baloch; S Abraham; S Roberts; V A LiVolsi
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

2.  Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.

Authors:  Ian D Hay; William M McConahey; John R Goellner
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

3.  Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Authors:  Paul T C Wan; Mathew J Garnett; S Mark Roe; Sharlene Lee; Dan Niculescu-Duvaz; Valerie M Good; C Michael Jones; Christopher J Marshall; Caroline J Springer; David Barford; Richard Marais
Journal:  Cell       Date:  2004-03-19       Impact factor: 41.582

4.  Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer.

Authors:  Philip I Haigh; David R Urbach; Lorne E Rotstein
Journal:  Ann Surg Oncol       Date:  2004-12-27       Impact factor: 5.344

5.  RET/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto's thyroiditis share low-level recombination events with a subset of papillary carcinoma.

Authors:  Kerry J Rhoden; Kristian Unger; Giuliana Salvatore; Yesim Yilmaz; Volodymyr Vovk; Gennaro Chiappetta; Mazin B Qumsiyeh; Jay L Rothstein; Alfredo Fusco; Massimo Santoro; Horst Zitzelsberger; Giovanni Tallini
Journal:  J Clin Endocrinol Metab       Date:  2006-04-04       Impact factor: 5.958

6.  Galectin-3, a marker of well-differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia.

Authors:  A Coli; Giulio Bigotti; F Zucchetti; F Negro; G Massi
Journal:  Histopathology       Date:  2002-01       Impact factor: 5.087

7.  Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.

Authors:  M F Beesley; K M McLaren
Journal:  Histopathology       Date:  2002-09       Impact factor: 5.087

8.  [Diagnosis of the follicular variant of papillary thyroid carcinoma. Significance of immunohistochemistry].

Authors:  Serge Guyétant; Sophie Michalak; Isabelle Valo; Jean-Paul Saint-André
Journal:  Ann Pathol       Date:  2003-02       Impact factor: 0.407

9.  Apoptosis-inducing factor regulates death in peripheral T cells.

Authors:  Smita Srivastava; Hridesh Banerjee; Ashutosh Chaudhry; Anupriya Khare; Apurva Sarin; Anna George; Vineeta Bal; Jeannine M Durdik; Satyajit Rath
Journal:  J Immunol       Date:  2007-07-15       Impact factor: 5.422

10.  Mutations of the BRAF gene in human cancer.

Authors:  Helen Davies; Graham R Bignell; Charles Cox; Philip Stephens; Sarah Edkins; Sheila Clegg; Jon Teague; Hayley Woffendin; Mathew J Garnett; William Bottomley; Neil Davis; Ed Dicks; Rebecca Ewing; Yvonne Floyd; Kristian Gray; Sarah Hall; Rachel Hawes; Jaime Hughes; Vivian Kosmidou; Andrew Menzies; Catherine Mould; Adrian Parker; Claire Stevens; Stephen Watt; Steven Hooper; Rebecca Wilson; Hiran Jayatilake; Barry A Gusterson; Colin Cooper; Janet Shipley; Darren Hargrave; Katherine Pritchard-Jones; Norman Maitland; Georgia Chenevix-Trench; Gregory J Riggins; Darell D Bigner; Giuseppe Palmieri; Antonio Cossu; Adrienne Flanagan; Andrew Nicholson; Judy W C Ho; Suet Y Leung; Siu T Yuen; Barbara L Weber; Hilliard F Seigler; Timothy L Darrow; Hugh Paterson; Richard Marais; Christopher J Marshall; Richard Wooster; Michael R Stratton; P Andrew Futreal
Journal:  Nature       Date:  2002-06-09       Impact factor: 49.962

View more
  6 in total

1.  Digital gene expression analysis might aid in the diagnosis of thyroid cancer.

Authors:  H Armanious; B Adam; D Meunier; K Formenti; I Izevbaye
Journal:  Curr Oncol       Date:  2020-05-01       Impact factor: 3.677

2.  Clinical prognosis and bioinformatic analysis of primary thyroid lymphoma.

Authors:  Zhimin Bai; Lingyu Li; Tao Guan; Jiangtao Wang; Jin Zhao; Liping Su
Journal:  Medicine (Baltimore)       Date:  2021-02-12       Impact factor: 1.817

3.  The effect of the area proportion of the metastatic lesion within the central metastatic lymph node on response to therapy in papillary thyroid carcinoma.

Authors:  Liuhong Shi; Liang Zhou; Jianbiao Wang; Lei Jin; Yinjiao Lei; Lian Xia; Lei Xie
Journal:  Oncol Lett       Date:  2021-02-12       Impact factor: 2.967

4.  Prediction Model of Pathologic Central Lymph Node Negativity in cN0 Papillary Thyroid Carcinoma.

Authors:  Xiujie Shu; Lingfeng Tang; Daixing Hu; Yuanyuan Wang; Ping Yu; Zhixin Yang; Chang Deng; Denghui Wang; Xinliang Su
Journal:  Front Oncol       Date:  2021-09-27       Impact factor: 6.244

5.  Circular RNA profiling reveals a potential role of hsa_circ_IPCEF1 in papillary thyroid carcinoma.

Authors:  Min Guo; Yushuang Sun; Junzhu Ding; Yong Li; Sihan Yang; Yanna Zhao; Xin Jin; Shan-Shan Li
Journal:  Mol Med Rep       Date:  2021-06-24       Impact factor: 2.952

6.  Thyroid antibody status exerts insignificant effect on lymph node metastasis of thyroid cancer.

Authors:  Youxing Zhou; Zhiqiang Sun; Yan Zhou; Cheng Tang; Xiaopeng Jiang; Fuliang Sun; Yi Ma; Jianfeng Cheng
Journal:  Transl Cancer Res       Date:  2020-10       Impact factor: 1.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.